Analysts Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $57.09
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month […]
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month […]
